Is There Any Clinical Value of Adding 123I-Metaiodobenzylguanidine Myocardial Scintigraphy to 123I-Ioflupane (DaTscan) in the Differential Diagnosis of Parkinsonism?
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
pubmed:
15
5
2020
medline:
23
10
2020
entrez:
15
5
2020
Statut:
ppublish
Résumé
The aim of the study is to evaluate the impact of myocardial I-metaiodobenzylguanidine (MIBG) in the diagnosis, clinical management, and differential diagnosis of Parkinson disease (PD) and non-PD parkinsonism. The study enrolled 41 patients with parkinsonism. An initial diagnosis was reached after thorough clinical and imaging evaluation. After 2 to 5 years of follow-up, a final diagnosis was established. All patients underwent, soon after their initial visit, presynaptic striatal DaT scintigraphy with I-FP-CIT (DaTscan) and I-MIBG myocardial scintigraphy. DaTscan is not specific to distinguish among different types of neurodegenerative parkinsonism. I-MIBG myocardial scintigraphy displays the functional status of cardiac sympathetic nerves, which is reduced in PD/dementia with Lewy bodies (DLB) and normal in atypical parkinsonian syndromes and secondary or nondegenerative parkinsonism. No patients showed adverse effects during or after both scintigraphies. A positive DaTscan was found in all patients in the PD/DLB group (17/17) and in 15 of 24 patients in the non-PD group. Myocardial I-MIBG scintigraphy was associated with lower sensitivity (82% vs 100%) but higher specificity than DaTscan (79% vs 38%) in diagnosis PD/DLB from non-PD parkinsonism. A positive scan result on both techniques, to confirm diagnosis of PD/DLB, significantly improved the specificity of DaTscan, from 38% to 75%, with no reduction in sensitivity. Myocardial I-MIBG imaging provides complementary value to I-FP-CIT in the proper diagnosis, treatment plan, and differential diagnosis between PD and other forms of parkinsonism.
Identifiants
pubmed: 32404715
doi: 10.1097/RLU.0000000000003098
pii: 00003072-202008000-00002
doi:
Substances chimiques
Nortropanes
0
Radiopharmaceuticals
0
Tropanes
0
2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane
155797-99-2
3-Iodobenzylguanidine
35MRW7B4AD
ioflupane
VF232WE742
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
588-593Références
Brigo F, Matinella A, Erro R, et al. [123I]FP-CIT SPECT (DaTscan) may be a useful tool to differentiate between Parkinson’s disease and vascular or drug-induced parkinsonisms: a meta-analysis. Eur J Neurol. 2014;21:1369–e90.
Sadasivan S, Friedman JH. Experience with DaTscan at a tertiary referral center. Parkinsonism Relat Disord. 2015;21:42–45.
Orimo S, Suzuki M, Inaba A, et al. 123I-MIBG myocardial scintigraphy for differentiating Parkinson’s disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2012;18:494–500.
Brooks DJ. Imaging approaches to Parkinson disease. J Nucl Med. 2010;51:596–609.
Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson’s disease. Lancet Neurol. 2006;5:75–86.
Spiegel J, Hellwig D, Samnick S, et al. Striatal FP-CIT uptake differs in the subtypes of early Parkinson’s disease. J Neural Transm (Vienna). 2007;114:331–335.
Joutsa J, Gardberg M, Röyttä M, et al. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord. 2014;20:840–844.
Südmeyer M, Antke C, Zizek T, et al. Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: a multidimensional statistical approach. J Nucl Med. 2011;52:733–740.
Brigo F, Erro R, Marangi A, et al. Differentiating drug-induced parkinsonism from Parkinson’s disease: an update on non-motor symptoms and investigations. Parkinsonism Relat Disord. 2014;20:808–814.
Treglia G, Cason E, Stefanelli A, et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res. 2012;22:43–55.
Spiegel J. Diagnostic and pathophysiological impact of myocardial MIBG scintigraphy in Parkinson’s disease. Parkinsons Dis. 2010;2010.
Treglia G, Stefanelli A, Cason E, et al. Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson’s disease and multiple-system atrophy: a systematic review and a meta-analysis. Clin Neurol Neurosurg. 2011;113:823–829.
Nagayama H, Ueda M, Yamazaki M, et al. Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov Disord. 2010;25:1744–1747.
Orimo S, Amino T, Yokochi M, et al. Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2. Mov Disord. 2005;20:1350–1353.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–442.
Gerasimou G, Costa DC, Papanastasiou E, et al. SPECT study with I-123-ioflupane (DaTscan) in patients with essential tremor. Is there any correlation with Parkinson’s disease? Ann Nucl Med. 2012;26:337–344.
Pagano G, Niccolini F, Politis M. Imaging in Parkinson’s disease. Clin Med (Lond). 2016;16:371–375.
Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2013;84:1288–1295.
Lucio CG, Vincenzo C, Antonio R, et al. Neurological applications for myocardial MIBG scintigraphy. Nucl Med Rev Cent East Eur. 2013;16:35–41.
Chiaravalloti A, Stefani A, Di Biagio D, et al. Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson’s disease. Ann Nucl Med. 2013;27:444–451.
Muxí A, Paredes P, Navales I, et al. Diagnostic cutoff points for 123I-MIBG myocardial scintigraphy in a Caucasian population with Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2011;38:1139–1146.
Treglia G, Cason E, Cortelli P, et al. Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 ioflupane single photon emission computed tomography in Lewy body diseases: complementary or alternative techniques? J Neuroimaging. 2014;24:149–154.
Uyama N, Otsuka H, Shinya T, et al. The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes. Nucl Med Commun. 2017;38:487–492.
Davidson A, Georgiopoulos C, Dizdar N, et al. Comparison between visual assessment of dopaminergic degeneration pattern and semi-quantitative ratio calculations in patients with PD and APS using DaTscan SPECT. Ann Nucl Med. 2014;28:851–859.
Knudsen GM, Karlsborg M, Thomsen G, et al. Imaging of dopamine transporters and D2 receptors in patients with PD and MSA. Eur J Nucl Med Mol Imaging. 2004;31:1631–1638.
Pirker W, Djamshidian S, Asenbaum S, et al. Progression of dopamine degeneration in PD and atypical parkinsonism: a longitudinal β-CIT SPECT study. Mov Disord. 2002;17:45–53.
Pirker W, Asenbaum S, Bancsits G, et al. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord. 2000;15:1158–1167.
Mizutani Y, Ito S, Murate K, et al. Retrospective analysis of parkinsonian patients exhibiting normal (123)I-MIBG cardiac uptake. J Neurol Sci. 2015;359:236–240.
Kim JS, Park HE, Park IS, et al. Normal ‘heart’ in Parkinson’s disease: is this a distinct clinical phenotype? Eur J Neurol. 2017;24:349–356.
Isaias IU, Canesi M, Benti R, et al. Striatal dopamine transporter abnormalities in patients with essential tremor. Nucl Med Commun. 2008;29:349–353.
Shahed J, Jankovic J. Exploring the relationship between essential tremor and Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:67–76.
Spanaki C, Plaitakis A. Essential tremor in Parkinson’s disease kindreds from population of similar genetic background. Mov Disord. 2009;24:1662–1668.